Back to News
Market Impact: 0.4
Syndax's Phase 2 MAXPIRe Trial Of Axatilimab Misses Primary Endpoint In IPF; Shares Plunge
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Syndax Pharmaceuticals said its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint: the annualized rate of decline in forced vital capacity (FVC). The report provides no further trial results or share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.55
Ticker Sentiment
SNDX-0.85
More News
- Why UnitedHealth Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Stocks making the biggest moves premarket: JPMorgan Chase, Micron, UnitedHealth & more
- Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
- Stocks making the biggest moves midday: Apple, Meta Platforms, Bumble, Fermi, Goldman Sachs & more
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Alternative Data Due Diligence for Institutional Investors
- Introducing AllMind: A New Data & AI Workspace for Institutional Investors